KDR and neoplasm: Sorafenib inhibits VEGFR1, VEGFR2, VEGFR3, PDGFR, c-KIT, FLT-3, RET, and RAF kinases, and is known to induce tumor cell apoptosis via MAPK signaling as well as angiogenesis.